- Home
- ATOS vs DRTS Comparison
ATOS vs DRTS Comparison
Compare ATOS & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- DRTS
- Stock Information
- Founded
- ATOS 2009
- DRTS 2015
- Country
- ATOS United States
- DRTS Israel
- Employees
- ATOS N/A
- DRTS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- ATOS Health Care
- DRTS Health Care
- Exchange
- ATOS Nasdaq
- DRTS Nasdaq
- Market Cap
- ATOS 140.9M
- DRTS 159.1M
- IPO Year
- ATOS 2012
- DRTS N/A
- Fundamental
- Price
- ATOS $0.96
- DRTS $3.10
- Analyst Decision
- ATOS Strong Buy
- DRTS Strong Buy
- Analyst Count
- ATOS 3
- DRTS 2
- Target Price
- ATOS $7.00
- DRTS $8.00
- AVG Volume (30 Days)
- ATOS 952.6K
- DRTS 62.8K
- Earning Date
- ATOS 11-12-2024
- DRTS 11-19-2024
- Dividend Yield
- ATOS N/A
- DRTS N/A
- EPS Growth
- ATOS N/A
- DRTS N/A
- EPS
- ATOS N/A
- DRTS N/A
- Revenue
- ATOS N/A
- DRTS N/A
- Revenue This Year
- ATOS N/A
- DRTS N/A
- Revenue Next Year
- ATOS N/A
- DRTS N/A
- P/E Ratio
- ATOS N/A
- DRTS N/A
- Revenue Growth
- ATOS N/A
- DRTS N/A
- 52 Week Low
- ATOS $0.73
- DRTS $1.75
- 52 Week High
- ATOS $2.31
- DRTS $3.40
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- DRTS 74.53
- Support Level
- ATOS $1.17
- DRTS $2.88
- Resistance Level
- ATOS $1.30
- DRTS $3.20
- Average True Range (ATR)
- ATOS 0.08
- DRTS 0.10
- MACD
- ATOS -0.02
- DRTS 0.00
- Stochastic Oscillator
- ATOS 1.09
- DRTS 81.25
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.